News Headlines

  1. Wacker Biotech And Eclipsebio Announce Strategic Collaboration To Advance RNA Medicine Development And Production 8/4/2026

    Wacker Biotech, a leading contract development and manufacturing organization (CDMO) wholly owned by Wacker Chemie AG, and Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced a strategic collaboration.

  2. SOPHiA GENETICS Enters Collaboration To Develop Companion Diagnostics For Precision Oncology Therapies 8/4/2026

    SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

  3. Niagen Bioscience Selects Global Drug Development Pioneer Evotec To Advance Preclinical Development For NB4168 8/3/2026

    Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.

  4. Ginkgo Bioworks And Acies Bio Partner To Expand Global Access To High-Performance Aspergillus Niger Strains For Protein Production 8/3/2026

    Ginkgo Bioworks and Acies Bio, a European biotechnology company specializing in microbial strain development, bioprocess development, scale-up, and manufacturing, today announced a partnership that will combine one of Ginkgo's most versatile microbial "factories" with Acies to support companies around the world.

  5. Genezen And The Raiden Science Foundation Announce Partnership For AAV9 Gene Replacement Therapy For UBA5 Clinical Trial 8/3/2026

    Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), and the Raiden Science Foundation (RSF), a parent-led rare disease organization, today announced a manufacturing partnership for an AAV Serotype 9 gene replacement therapy for UBA5 disorder.

  6. Taysha Gene Therapies And Catalent Expand Strategic Partnership To Include Future Commercial Manufacturing Support Of TSHA-102 Gene Therapy For Rett Syndrome 8/3/2026

    Taysha Gene Therapies, Inc.,(Taysha),a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc.,(Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha’s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval.

  7. Fujifilm And Taiho Pharmaceutical Enter Into Strategic Partnership For Development Of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies 8/3/2026

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) and Taiho Pharmaceutical Co., Ltd. (President and Representative Director: Masayuki Kobayashi)today announced that they have entered into a strategic partnership agreement for the development of manufacturing technologies for next-generation antibody-drug conjugates (ADCs).

  8. Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI As A Separate Company To Commercialize And Expand Its Multi-Agent AI Co-Scientist Platform For The Transformation Of Medicine 8/3/2026

    Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma.

  9. Tasrif Pharmaceutical Granted Second U.S. Patent For CD155-Targeting Antibody Developed With Abzena's Humanization & Immunogenicity Platforms 7/31/2026

    On July 29, 2026, Abzen’s customer Tasrif Pharmaceutical, LLC announced the grant of its second U.S. Patent, expanding its intellectual property targeting the Poliovirus Receptor (CD155/PVR). 

  10. Abzena's Customer Promatix Awarded An Innovate UK Biomedical Catalyst Grant To Advance Cis-Bispecific ADC 7/31/2026

    On July 28, 2026, Promatix Biosciences Ltd, an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, announced that it has been awarded a grant under the Innovate UK Biomedical Catalyst 2025: Industry-led R&D small projects competition.